| Source: |
| Type: |
| Cytochrome c ** The term "release of cytochrome c" ** an increase in level for the cytosol. Small hemeprotein found loosely associated with the inner membrane of the mitochondrion where it plays a critical role in cellular respiration. Cytochrome c is highly water-soluble, unlike other cytochromes. It is capable of undergoing oxidation and reduction as its iron atom converts between the ferrous and ferric forms, but does not bind oxygen. It also plays a major role in cell apoptosis. The term "release of cytochrome c" refers to a critical step in the process of programmed cell death, also known as apoptosis. In its new location—the cytosol—cytochrome c participates in the apoptotic signaling pathway by helping to form the apoptosome, which activates caspases that execute cell death. Cytochrome c is a small protein normally located in the mitochondrial intermembrane space. Its primary role in healthy cells is to participate in the electron transport chain, a process that helps produce energy (ATP) through oxidative phosphorylation. Mitochondrial outer membrane permeability leads to the release of cytochrome c from the mitochondria into the cytosol. The release of cytochrome c is a pivotal event in apoptosis where cytochrome c moves from the mitochondria to the cytosol, initiating a chain reaction that leads to programmed cell death. On the one hand, cytochrome c can promote cancer cell survival and proliferation by regulating the activity of various signaling pathways, such as the PI3K/AKT pathway. This can lead to increased cell growth and resistance to apoptosis, which are hallmarks of cancer. On the other hand, cytochrome c can also induce apoptosis in cancer cells by interacting with other proteins, such as Apaf-1 and caspase-9. This can lead to the activation of the intrinsic apoptotic pathway, which can result in the death of cancer cells. Overexpressed in Breast, Lung, Colon, and Prostrate. Underexpressed in Ovarian, and Pancreatic. |
| 5113- | JG, | Juglone in Oxidative Stress and Cell Signaling |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 5114- | JG, | Juglone, from Juglans mandshruica Maxim, inhibits growth and induces apoptosis in human leukemia cell HL-60 through a reactive oxygen species-dependent mechanism |
| - | in-vitro, | AML, | HL-60 |
| 1927- | JG, | Juglone-induced apoptosis in human gastric cancer SGC-7901 cells via the mitochondrial pathway |
| - | in-vitro, | GC, | SGC-7901 |
| 1926- | JG, | Mechanism of juglone-induced apoptosis of MCF-7 cells by the mitochondrial pathway |
| - | in-vitro, | BC, | MCF7 |
| 1924- | JG, | Juglone triggers apoptosis of non-small cell lung cancer through the reactive oxygen species -mediated PI3K/Akt pathway |
| - | in-vitro, | Lung, | A549 |
| 1923- | JG, | Mechanism of Juglone-Induced Cell Cycle Arrest and Apoptosis in Ishikawa Human Endometrial Cancer Cells |
| - | in-vitro, | Endo, | NA |
| 8095- | KAE, | Kaempferol: A Key Emphasis to Its Anticancer Potential |
| - | Review, | Var, | NA |
| 8105- | KAE, | Chemo-preventive and therapeutic effect of the dietary flavonoid kaempferol: A comprehensive review |
| - | Review, | Var, | NA |
| 8060- | KAE, | Mechanisms underlying apoptosis-inducing effects of Kaempferol in HT-29 human colon cancer cells |
| - | in-vitro, | CRC, | HT-29 |
| 8072- | KAE, | Natural defense against colorectal cancer: the effects of kaempferol on epigenetics, apoptosis, inflammation, oxidative stress, and cell proliferation |
| - | Review, | CRC, | NA |
| 8080- | KAE, | Hepatoprotective Effect of Kaempferol—A Review |
| - | Review, | Nor, | NA |
| 8055- | KAE, | Molecular Mechanisms of the Anticancer Activity of the Flavonoid Kaempferol: A Comprehensive Review |
| - | Review, | Var, | NA |
| 8161- | LapC, | Lapachol is a novel ribosomal protein S6 kinase 2 inhibitor that suppresses growth and induces intrinsic apoptosis in esophageal squamous cell carcinoma cells |
| - | in-vitro, | ESCC, | KYSE-30 | - | in-vitro, | ESCC, | KYSE450 | - | in-vitro, | ESCC, | KYSE-510 |
| 8175- | Las, | Lasiodin Inhibits Proliferation of Human Nasopharyngeal Carcinoma Cells by Simultaneous Modulation of the Apaf-1/Caspase, AKT/MAPK and COX-2/NF-κB Signaling Pathways |
| - | in-vitro, | NPC, | NA |
| 8237- | LCA, | Role of Licochalcone A in Potential Pharmacological Therapy: A Review |
| - | Review, | Var, | NA |
| 8245- | LCA, | Licochalcone A Upregulates Nrf2 Antioxidant Pathway and Thereby Alleviates Acetaminophen-Induced Hepatotoxicity |
| - | in-vivo, | LiverDam, | NA |
| 8243- | LCA, | Licochalcone A Inhibits Cellular Motility by Suppressing E-cadherin and MAPK Signaling in Breast Cancer |
| - | in-vitro, | BC, | MDA-MB-231 |
| 8254- | LCA, | Geld, | Licochalcone A enhances geldanamycin-induced apoptosis through reactive oxygen species-mediated caspase activation |
| - | in-vitro, | Ovarian, | NA |
| 8209- | LCA, | Licochalcone A Exerts Anti-Cancer Activity by Inhibiting STAT3 in SKOV3 Human Ovarian Cancer Cells |
| - | in-vitro, | Ovarian, | SKOV3 |
| 8235- | LCA, | Anticancer effects of licochalcones: A review of the mechanisms |
| - | Review, | Var, | NA |
| 8222- | LCA, | Licochalcone A Induces Cholangiocarcinoma Cell Death Via Suppression of Nrf2 and NF-κB Signaling Pathways |
| - | in-vitro, | CCA, | KKU-100 | - | in-vitro, | CCA, | KKU-213 | - | in-vitro, | CCA, | KKU-214 | - | in-vitro, | CCA, | KKU-156 | - | in-vitro, | 0-Reserved, | KKU-452 |
| 8236- | LE, | Licorice (Glycyrrhiza glabra L.)-Derived Phytochemicals Target Multiple Signaling Pathways to Confer Oncopreventive and Oncotherapeutic Effects |
| - | Review, | Var, | NA |
| 8279- | LE, | 18β-Glycyrrhetinic Acid Has Anti-Cancer Effects via Inducing Apoptosis and G2/M Cell Cycle Arrest, and Inhibiting Migration of A549 Lung Cancer Cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H23 | - | in-vitro, | Lung, | H460 |
| 8294- | lign, | Secoisolariciresinol diglucoside induces pyroptosis by activating caspase-1 to cleave GSDMD in colorectal cancer cells |
| - | vitro+vivo, | CRC, | LoVo | - | in-vitro, | CRC, | SW-620 | - | in-vitro, | NA, | SW480 | - | in-vitro, | CRC, | HT-29 | - | in-vitro, | CRC, | HCT116 |
| 8403- | LT, | Luteolin induces apoptotic cell death via antioxidant activity in human colon cancer cells |
| - | in-vitro, | CRC, | HT-29 |
| 8401- | LT, | Multi-Faceted Role of Luteolin in Cancer Metastasis: EMT, Angiogenesis, ECM Degradation and Apoptosis |
| - | Review, | Var, | NA |
| - | in-vivo, | AD, | NA |
| 2923- | LT, | Luteolin induces apoptosis through endoplasmic reticulum stress and mitochondrial dysfunction in Neuro-2a mouse neuroblastoma cells |
| - | in-vitro, | neuroblastoma, | NA |
| 2903- | LT, | Luteolin induces apoptosis by ROS/ER stress and mitochondrial dysfunction in gliomablastoma |
| - | in-vitro, | GBM, | U251 | - | in-vitro, | GBM, | U87MG | - | in-vivo, | NA, | NA |
| 2904- | LT, | Luteolin from Purple Perilla mitigates ROS insult particularly in primary neurons |
| - | in-vitro, | Park, | SK-N-SH | - | in-vitro, | AD, | NA |
| 2912- | LT, | Luteolin: a flavonoid with a multifaceted anticancer potential |
| - | Review, | Var, | NA |
| 2919- | LT, | Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence |
| - | Review, | Var, | NA |
| 2916- | LT, | Antioxidative and Anticancer Potential of Luteolin: A Comprehensive Approach Against Wide Range of Human Malignancies |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3263- | Lyco, | Lycopene protects against myocardial ischemia-reperfusion injury by inhibiting mitochondrial permeability transition pore opening |
| - | in-vitro, | Nor, | H9c2 | - | in-vitro, | Stroke, | NA |
| 8420- | Lyco, | Anticancer activity of lycopene in HT-29 colon cancer cell line |
| - | in-vitro, | CRC, | HT-29 |
| 4791- | Lyco, | Investigating into anti-cancer potential of lycopene: Molecular targets |
| - | Review, | Var, | NA |
| 4794- | Lyco, | Anticancer Effect of Lycopene in Gastric Carcinogenesis |
| - | Review, | GC, | NA |
| 2545- | M-Blu, | Reversing the Warburg Effect as a Treatment for Glioblastoma |
| - | in-vitro, | GBM, | U87MG | - | NA, | AD, | NA | - | in-vitro, | GBM, | A172 | - | in-vitro, | GBM, | T98G |
| 8524- | MAG, | Magnolol induces apoptosis via inhibiting the EGFR/PI3K/Akt signaling pathway in human prostate cancer cells |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | CRC, | HCT116 |
| 8521- | MAG, | Magnolol induces apoptosis via caspase-independent pathways in non-small cell lung cancer cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H520 | - | in-vitro, | Lung, | NCI-H441 |
| 8497- | MAG, | Magnolol induces apoptosis in MCF-7 human breast cancer cells through G2/M phase arrest and caspase-independent pathway |
| - | in-vitro, | BC, | MCF7 |
| 4534- | MAG, | Molecular mechanisms of apoptosis induced by magnolol in colon and liver cancer cells |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | CRC, | COLO205 |
| 4531- | MAG, | Magnolol-induced apoptosis in HCT-116 colon cancer cells is associated with the AMP-activated protein kinase signaling pathway |
| - | in-vitro, | CRC, | HCT116 |
| 4519- | MAG, | Magnolol: A Neolignan from the Magnolia Family for the Prevention and Treatment of Cancer |
| - | Review, | Var, | NA |
| 8536- | Matr, | Effect of matrine against breast cancer by downregulating the vascular endothelial growth factor via the Wnt/β-catenin pathway |
| - | vitro+vivo, | BC, | 4T1 | - | in-vitro, | BC, | MCF7 |
| 8560- | Matr, | Matrine: A Promising Natural Product With Various Pharmacological Activities |
| - | Review, | AD, | NA | - | Review, | Stroke, | NA | - | Review, | Var, | NA |
| 8552- | Matr, | Matrine exerts its neuroprotective effects by modulating multiple neuronal pathways |
| - | Review, | AD, | NA |
| 8626- | MBZ, | The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells |
| - | in-vitro, | Lung, | NA |
| 8632- | MBZ, | Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo |
| - | vitro+vivo, | Lung, | NA |
| 8648- | MBZ, | Mebendazole as a Candidate for Drug Repurposing in Oncology: An Extensive Review of Current Literature |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:77 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid